The aim of this study was to evaluate disease-free survival in paediatric patients treated for Hodgkin’s lymphoma using 67Ga total body scintigraphy and thoracic SPECT. Methods: Between October 1996 and October 2001, twenty—seven patients with Hodgkin’s lymphoma were examined; only in nineteen was performed both 67Ga total body scintigraphy and thoracic SPECT at diagnosis and after chemotherapy. The patients were administered 0.07 mCi/kg (2.59 MBq) as a single intravenous bolus injection. The whole body was scanned at twenty-four, thirty-six and seventy-two hours and the SPECT at forty-eight hours after injection, using dual head cameras (Axis-Picker) with suitable collimators. We screened the results of thoracic RX, neck, thoracic and abdominal TAC, neck and abdominal ultrasonography, 99mTc-HDP whole body bone scintigraphy at diagnosis and after chemotherapy. Results: The 19 patients (eleven male and eight female; age range 6-15 year; mean age 10.47 year) were affected by Hodgkin`s limphoma (all nodular-sclerosis variety). All patients had SPECT and TB scintigraphy negative for abnormal 67Ga uptake at the end of therapy. Seven patients had residual mass showed by other instrumental tests; four in mediastinum, two in neck and one in mediastinum and neck. During the follow-up there was only a case of recurrence in supraclavicular region, one year after the end of therapy; the 67Ga total body scintigraphy and thoracic SPECT was negative. Conclusion: This findings confirm the important role playing by 67Ga total body scintigraphy and thoracic SPECT to assess the nature of a residual mass after treatment and to predict disease-free survival.
67Ga SCINTIGRAPHY AFTER TREATMENT IN PAEDIATRIC PATIENTS WITH HODGKIN'S LYMPHOMA
SILVESTRO, Leandra;
2002-01-01
Abstract
The aim of this study was to evaluate disease-free survival in paediatric patients treated for Hodgkin’s lymphoma using 67Ga total body scintigraphy and thoracic SPECT. Methods: Between October 1996 and October 2001, twenty—seven patients with Hodgkin’s lymphoma were examined; only in nineteen was performed both 67Ga total body scintigraphy and thoracic SPECT at diagnosis and after chemotherapy. The patients were administered 0.07 mCi/kg (2.59 MBq) as a single intravenous bolus injection. The whole body was scanned at twenty-four, thirty-six and seventy-two hours and the SPECT at forty-eight hours after injection, using dual head cameras (Axis-Picker) with suitable collimators. We screened the results of thoracic RX, neck, thoracic and abdominal TAC, neck and abdominal ultrasonography, 99mTc-HDP whole body bone scintigraphy at diagnosis and after chemotherapy. Results: The 19 patients (eleven male and eight female; age range 6-15 year; mean age 10.47 year) were affected by Hodgkin`s limphoma (all nodular-sclerosis variety). All patients had SPECT and TB scintigraphy negative for abnormal 67Ga uptake at the end of therapy. Seven patients had residual mass showed by other instrumental tests; four in mediastinum, two in neck and one in mediastinum and neck. During the follow-up there was only a case of recurrence in supraclavicular region, one year after the end of therapy; the 67Ga total body scintigraphy and thoracic SPECT was negative. Conclusion: This findings confirm the important role playing by 67Ga total body scintigraphy and thoracic SPECT to assess the nature of a residual mass after treatment and to predict disease-free survival.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
